EXCLUSIVE: ProSomnus' Device Therapy Better Than Philip's Device(s) For Sleep-Related Breathing Disorder, Study Shows
Portfolio Pulse from Vandana Singh
ProSomnus Inc (NASDAQ:OSA) announced updated data from the FLOSAT study, which compares its precision oral appliance therapy (OAT) to Koninklijke Philips NV's (NYSE:PHG) continuous positive airway pressure (CPAP) therapy for Obstructive Sleep Apnea. The data shows that ProSomnus' OAT is effective and preferred by patients, with twice the mean disease alleviation as CPAP. OSA shares closed 3.06% higher at $1.01 on Tuesday.
August 23, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProSomnus' OAT shows promising results in the FLOSAT study, potentially boosting its market position. OSA shares rose 3.06%.
The positive results from the FLOSAT study indicate that ProSomnus' OAT is effective and preferred by patients over Philips' CPAP. This could potentially increase demand for ProSomnus' product, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Philips' CPAP therapy was outperformed by ProSomnus' OAT in the FLOSAT study, which could negatively impact its market position.
The FLOSAT study results show that ProSomnus' OAT is more effective and preferred by patients over Philips' CPAP. This could potentially decrease demand for Philips' product, negatively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80